This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): duloxetine, Cymbalta delayed-release, Yentreve, Xeristar, AriClaim, LY248686
Description: Cymbalta works by maximizing the presence in the brain of two messenger chemicals, serotonin and norepinephrine. It is a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SSNRI), meaning that it blocks reuptake of these neurotransmitters. Cymbalta has less effect on dopamine reuptake. Though the exact mechanisms by which reuptake blockade helps symptoms is unknown, SSNRI blockade of norephinephine reuptake is thought to be important for reducing neuropathic pain, which is also seen with the older tricyclic antidepressants but not with the SSRIs (Selective Serotonin Reuptake Inhibitors).
Revenue splits are BioMedTracker estimates.
Eli Lilly and Boehringer Ingelheim
In February 2006, Eli Lilly and Company and Boehringer Ingelheim announced an alliance that changed the nature of its contractual agreements for Yentreve/AriClaim/Cymbalta/Xeristar. Lilly will repurchase sole worldwide commercialization rights to Yentreve/AriClaim and will continue marketing this indication outside the U.S. The Lilly-Boehringer Ingelheim agreement to market duloxetine outside the U.S. under the trademarks Cymbalta/Xeristar remains unaffected by the announcement. Lilly owns the rights to commercialize Cymbalta in the United States.
In 2010, Eli Lilly signed an agreement with Boehringer Ingelheim to terminate the existing arrangement and re-acquire the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan. Lilly paid Boehringer Ingelheim $400 million upfront and will pay a royalty on sales through the end of...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd.
Pink Sheet Cymbalta FDA Reviewers
Pink Sheet Cymbalta Clinical Development
Additional information available to subscribers only: